產(chǎn)品屬性：
產(chǎn)品名稱 | SM1-71 |
規(guī)格 | 5 mg、10 mg、25 mg、50 mg、100 mg |
貨號 | EY-01Y12939 |
Cas No.: 2088179-99-9
別名: N/A
化學(xué)名: N/A
分子式: C24H26ClN7O
分子量: 463.96
溶解度: N/A
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines[1][2][3].SM1-71 (0.001-100 μM; 72 h) potently inhibits the proliferation of H23 and Calu-6 non-small cell lung cancer cell lines with a concentration-dependent manner[1].SM1-71 (72 h) induces potent cytotoxicity with nanomolar values for GR50 and negative GRmax values in eight of 11 cancer cell lines[2].[1]. Rao S, et, al. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chem Biol. 2019 Jun 20; 26(6): 818-829.e9. [2]. Rao S, et, al. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J Biol Chem. 2019 May 24;294(21):8664-8673. [3]. Tan L, et, al. Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 Feb 1; 25(3): 838-846.
特別提醒公司產(chǎn)品僅供科研使用
